Delving into the Latest Updates on Ningbo Combireg Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Endocrinology and Metabolic Disease

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

Tubulin	1

主要目的： 1.评估注射用信立他赛的安全性和耐受性。 2.确定注射用信立他赛的最大耐受剂量（MTD）和/或Ⅱ期临床试验推荐剂量（RP2D）。次要目的： 1.评估注射用信立他赛的药代动力学（PK）特征。 2.初步评估注射用信立他赛的抗肿瘤疗效。探索目的： 1.监测注射用信立他赛药效学相关的生物标志物：在受试者中寻找有效的生物标志物。 2.探索注射用信立他赛抗肿瘤的预测性生物标志物：包括肿瘤组织核苷酸结合寡聚化结构域（NOD）1/2等的表达水平。

[Translation]

Main objectives: 1. Evaluate the safety and tolerability of xinlitaxel for injection. 2. Determine the maximum tolerated dose (MTD) and/or recommended dose (RP2D) of xinlitaxel for injection. Secondary objectives: 1. Evaluate the pharmacokinetic (PK) characteristics of xinlitaxel for injection. 2. Preliminary evaluation of the anti-tumor efficacy of xinlitaxel for injection. Exploration objectives: 1. Monitor biomarkers related to the pharmacodynamics of xinlitaxel for injection: Find effective biomarkers in subjects. 2. Explore predictive biomarkers for the anti-tumor effect of xinlitaxel for injection: including the expression levels of nucleotide binding oligomerization domain (NOD) 1/2 in tumor tissues.

Start Date17 Sep 2021

Sponsor / Collaborator

Ningbo Combireg Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Ningbo Combireg Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Ningbo Combireg Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Ningbo Combireg Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Ningbo Combireg Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Phase 1 Clinical

Login to view more data